Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Rheumatology Reports
Erschienen in: Current Rheumatology Reports 12/2014

01.12.2014 | Pediatric Rheumatology (S Ozen, Section Editor)

Enthesitis-Related Arthritis: Time to Re-define?

verfasst von: Angela R. Bryan, C. Egla Rabinovich

Erschienen in: Current Rheumatology Reports | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood. Enthesitis-related arthritis (ERA) is one of the seven JIA subtypes classified by the International League of Associations for Rheumatology (ILAR). Due to inclusion and exclusion criteria, a pitfall of the ERA category is that it does not include all subsets of juvenile spondyloarthropathy, with many children ending up in the undifferentiated category. The ERA nomenclature also does not have a method for distinguishing between axial and peripheral disease, two phenotypes which vary in presentation and treatment requirements. This distinction is very important given the overall poor prognosis seen in ERA patients, specifically in those with axial involvement. Since axial involvement is more common and presents earlier than previously thought in ERA, the pediatric rheumatology community should develop more accurate and sensitive classification criteria based on disease course to assist in improving timely diagnosis and appropriate management.
Literatur
1.
Rosenberg AM, Petty RE. A syndrome of seronegative enthesopathy and arthropathy in children. Arthritis Rheum. 1982;25(9):1041–7.PubMedCrossRef
2.
Petty RE et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–2.PubMed
3.
Flato B et al. Long-term outcome and prognostic factors in enthesitis-related arthritis: a case-control study. Arthritis Rheum. 2006;54(11):3573–82.PubMedCrossRef
4.
Hofer M. Spondylarthropathies in children—are they different from those in adults? Best Pract Res Clin Rheumatol. 2006;20(2):315–28.PubMedCrossRef
5.
6.•
Ramanathan A, Srinivasalu H, Colbert RA. Update on juvenile spondyloarthritis. Rheum Dis Clin N Am. 2013;39(4):767–88. This is a review of juvenile spondyloarthropathies, including clinical features, genetics and therapeutic options.CrossRef
7.
Kasapcopur O et al. Evaluation of classification criteria for juvenile-onset spondyloarthropathies. Rheumatol Int. 2005;25(6):414–8.PubMedCrossRef
8.
Stoll ML et al. Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum. 2006;54(11):3564–72.PubMedCrossRef
9.••
Butbul Aviel Y et al. Juvenile psoriatic arthritis (JPsA): juvenile arthritis with psoriasis? Pediatr Rheumatol Online J. 2013;11(1):11. A cohort of children with JPsA were examined for unifying clinical features and long term outcomes.PubMedCentralPubMedCrossRef
10.
O’Shea FD et al. Comparison of clinical and radiographic severity of juvenile-onset versus adult-onset ankylosing spondylitis. Ann Rheum Dis. 2009;68(9):1407–12.PubMedCrossRef
11.••
Chen HA et al. Clinical, functional, and radiographic differences among juvenile-onset, adult-onset, and late-onset ankylosing spondylitis. J Rheumatol. 2012;39(5):1013–8. The differences between pediatric and adult onset ankylosing spondylitis examined in a large cohort of Taiwanese patients.PubMedCrossRef
12.
van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361–8.PubMedCrossRef
13.
Rudwaleit M et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777–83.PubMedCrossRef
14.
15.•
Fisher C et al. Enthesitis-related arthritis; a new era of understanding. Ann Paediatr Rheum. 2012;1(1):8–16. A review of differences between axial and peripheral ERA.CrossRef
16.
Chen J, Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol. 2006;33(4):722–31.PubMed
17.
Haibel H et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis. 2007;66(3):419–21.PubMedCentralPubMedCrossRef
18.
19.
Selvaag AM et al. Early disease course and predictors of disability in juvenile rheumatoid arthritis and juvenile spondyloarthropathy: a 3 year prospective study. J Rheumatol. 2005;32(6):1122–30.PubMed
20.
van der Heijde D et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther. 2009;11(4):R127.PubMedCentralPubMedCrossRef
21.
Althoff CE et al. Magnetic resonance imaging of active sacroiliitis: do we really need gadolinium? Eur J Radiol. 2009;71(2):232–6.PubMedCrossRef
22.•
Weiss PF et al. Enthesitis in an inception cohort of enthesitis-related arthritis. Arthritis Care Res (Hoboken). 2011;63(9):1307–12. Examination of characteristics of an inception cohort of patients with ERA.CrossRef
23.•
Pagnini I et al. Early predictors of juvenile sacroiliitis in enthesitis-related arthritis. J Rheumatol. 2010;37(11). Prospective study of ERA, examining incidence of sacroiliitis and early predictors for development of sacroiliitis.
24.•
Stoll ML et al. Spondyloarthritis in a pediatric population: risk factors for sacroiliitis. J Rheumatol. 2010;37(11):2402–8. Authors retrospectively examined risk factors for sacroiliitis, finding hip arthritis an important predictor.PubMedCentralPubMedCrossRef
25.
Bollow M et al. Use of dynamic magnetic resonance imaging to detect sacroiliitis in HLA-B27 positive and negative children with juvenile arthritides. J Rheumatol. 1998;25(3):556–64.PubMed
26.••
Vendhan K et al. Inflammatory changes of the lumbar spine in children and adolescents with enthesitis-related arthritis: magnetic resonance imaging findings. Arthritis Care Res (Hoboken). 2014;66(1):40–6. MRI abnormalities in the spine are examined and compared to a control population.CrossRef
27.
Minden K et al. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum. 2002;46(9):2392–401.PubMedCrossRef
28.•
Berntson L et al. HLA-B27 predicts a more chronic disease course in an 8-year followup cohort of patients with juvenile idiopathic arthritis. J Rheumatol. 2013;40(5):725–31. Large incident cohort of children with JIA prospectively examined and clinical characteristics examined and compared in HLA-B27 positive and negative patients.PubMedCrossRef
29.•
Donnithorne KJ, Cron RQ, Beukelman T. Attainment of inactive disease status following initiation of TNF-alpha inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active disease. J Rheumatol. 2011;38(12):2675–81. Retrospective, single site study of JIA patients with examination of attainment of inactive disease, and risk factors for persistent active disease after initiation of anti-TNF therapy.PubMedCentralPubMedCrossRef
30.••
Boiu S et al. Functional status in severe juvenile idiopathic arthritis in the biologic treatment era: an assessment in a French paediatric rheumatology referral centre. Rheumatology (Oxford). 2012;51(7):1285. Disability, pain and functional status examined in a cohort of patients with JIA.CrossRef
31.••
Weiss PF et al. Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the Childhood Arthritis and Rheumatology Research Alliance Registry. J Rheumatol. 2012;39(12):2341–51. Pain and health status examined in a large cross sectional study of JIA patients.PubMedCentralPubMedCrossRef
32.
Tse SM et al. Radiologic improvement of juvenile idiopathic arthritis-enthesitis-related arthritis following anti-tumor necrosis factor-alpha blockade with etanercept. J Rheumatol. 2006;33(6):1186–8.PubMed
Metadaten
Titel
Enthesitis-Related Arthritis: Time to Re-define?
verfasst von
Angela R. Bryan
C. Egla Rabinovich
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Current Rheumatology Reports / Ausgabe 12/2014
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-014-0466-z

Weitere Artikel der Ausgabe 12/2014

Current Rheumatology Reports 12/2014 Zur Ausgabe

Inflammatory Muscle Disease (RG Cooper, Section Editor)

Amyopathic Dermatomyositis: Definitions, Diagnosis, and Management

Health Economics and Quality of Life (M Harrison, Section Editor)

Economics of Stratified Medicine in Rheumatoid Arthritis

Pediatric Rheumatology (S Ozen, Section Editor)

The Presentation, Assessment, Pathogenesis, and Treatment of Calcinosis in Juvenile Dermatomyositis

Inflammatory Muscle Disease (RG Cooper, Section Editor)

Ongoing Developments in Sporadic Inclusion Body Myositis

Inflammatory Muscle Disease (RG Cooper, Section Editor)

Myositis Specific and Associated Autoantibodies in the Diagnosis and Management of Juvenile and Adult Idiopathic Inflammatory Myopathies

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise